Michael Venuti Ph.D.
Michael Venuti, Ph.D., chair of Infinity’s Research and Development Committee, is a consultant on drug discovery and development to biotechnology companies and venture capital groups. Previously, he was chief scientific officer of NeuroTherapeutics Pharma, from July 2011 to June 2013. From June 2010 to April 2011, Dr. Venuti served as president and chief executive officer of iPierian, Inc., a private biopharmaceutical company, after joining the company as president and chief scientific officer in February 2010. Prior to joining iPierian, Dr. Venuti served as chief executive officer and member of the board of directors of BioSeek, Inc., which was acquired by Asterand plc in February 2010. He previously served as chief executive officer and member of the board of directors of Discovery Partners International, a small molecule-based drug discovery services company. Dr. Venuti led the merger of Discovery Partners into Infinity Pharmaceuticals in 2006. From 2001 through 2005, he held positions as senior vice president, business development and Pharmacogenomics, and senior vice president, research and preclinical development at Celera Genomics, and served as the general manager of Celera South San Francisco. He served as senior vice president, research and preclinical development, at Axys Pharmaceuticals prior to its acquisition by Celera. Prior to joining Axys, Dr. Venuti was director of Bioorganic Chemistry at Genentech, Inc., and began his research career in medicinal chemistry at Syntex Research. Dr. Venuti holds an A.B. from Dartmouth College, and a Ph.D. in Organic Chemistry from The Massachusetts Institute of Technology.